185 related articles for article (PubMed ID: 9516936)
1. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.
Zamboni WC; Houghton PJ; Thompson J; Cheshire PJ; Hanna SK; Richmond LB; Lou X; Stewart CF
Clin Cancer Res; 1998 Feb; 4(2):455-62. PubMed ID: 9516936
[TBL] [Abstract][Full Text] [Related]
2. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice.
Stewart CF; Zamboni WC; Crom WR; Houghton PJ
Cancer Chemother Pharmacol; 1997; 40(3):259-65. PubMed ID: 9219511
[TBL] [Abstract][Full Text] [Related]
3. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of oral irinotecan against neuroblastoma xenografts.
Thompson J; Zamboni WC; Cheshire PJ; Richmond L; Luo X; Houghton JA; Stewart CF; Houghton PJ
Anticancer Drugs; 1997 Apr; 8(4):313-22. PubMed ID: 9180383
[TBL] [Abstract][Full Text] [Related]
5. Oral versus intraperitoneal administration of irinotecan in the treatment of human neuroblastoma in nude mice.
Choi SH; Tsuchida Y; Yang HW
Cancer Lett; 1998 Feb; 124(1):15-21. PubMed ID: 9500186
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
Thompson J; Zamboni WC; Cheshire PJ; Lutz L; Luo X; Li Y; Houghton JA; Stewart CF; Houghton PJ
Clin Cancer Res; 1997 Mar; 3(3):423-31. PubMed ID: 9815701
[TBL] [Abstract][Full Text] [Related]
7. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts.
Zucchetti M; Meco D; Di Francesco AM; Servidei T; Patriarca V; Cusano G; D'Incalci M; Forestieri D; Pisano C; Riccardi R
Cancer Chemother Pharmacol; 2010 Sep; 66(4):635-41. PubMed ID: 20091168
[TBL] [Abstract][Full Text] [Related]
9. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats.
Bansal T; Mishra G; Jaggi M; Khar RK; Talegaonkar S
Eur J Pharm Sci; 2009 Mar; 36(4-5):580-90. PubMed ID: 19135530
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
Klein CE; Gupta E; Reid JM; Atherton PJ; Sloan JA; Pitot HC; Ratain MJ; Kastrissios H
Clin Pharmacol Ther; 2002 Dec; 72(6):638-47. PubMed ID: 12496745
[TBL] [Abstract][Full Text] [Related]
11. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice.
Morton CL; Iacono L; Hyatt JL; Taylor KR; Cheshire PJ; Houghton PJ; Danks MK; Stewart CF; Potter PM
Cancer Chemother Pharmacol; 2005 Dec; 56(6):629-36. PubMed ID: 15918039
[TBL] [Abstract][Full Text] [Related]
12. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma.
Danks MK; Yoon KJ; Bush RA; Remack JS; Wierdl M; Tsurkan L; Kim SU; Garcia E; Metz MZ; Najbauer J; Potter PM; Aboody KS
Cancer Res; 2007 Jan; 67(1):22-5. PubMed ID: 17210679
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.
Mathijssen RH; Verweij J; Loos WJ; de Bruijn P; Nooter K; Sparreboom A
Br J Cancer; 2002 Jul; 87(2):144-50. PubMed ID: 12107833
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
Kawato Y; Furuta T; Aonuma M; Yasuoka M; Yokokura T; Matsumoto K
Cancer Chemother Pharmacol; 1991; 28(3):192-8. PubMed ID: 1855276
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
Ma MK; Zamboni WC; Radomski KM; Furman WL; Santana VM; Houghton PJ; Hanna SK; Smith AK; Stewart CF
Clin Cancer Res; 2000 Mar; 6(3):813-9. PubMed ID: 10741701
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
[TBL] [Abstract][Full Text] [Related]
17. The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model.
Dodds HM; Tobin PJ; Stewart CF; Cheshire P; Hanna S; Houghton P; Rivory LP
J Pharmacol Exp Ther; 2002 Nov; 303(2):649-55. PubMed ID: 12388647
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice.
Chu C; Abbara C; Tandia M; Polrot M; Gonin P; Farinotti R; Bonhomme-Faivre L
Fundam Clin Pharmacol; 2014 Dec; 28(6):652-60. PubMed ID: 24588516
[TBL] [Abstract][Full Text] [Related]
19. Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.
Monterrubio C; Paco S; Olaciregui NG; Pascual-Pasto G; Vila-Ubach M; Cuadrado-Vilanova M; Ferrandiz MM; Castillo-Ecija H; Glisoni R; Kuplennik N; Jungbluth A; de Torres C; Lavarino C; Cheung NKV; Mora J; Sosnik A; Carcaboso AM
J Control Release; 2017 Jun; 255():108-119. PubMed ID: 28412222
[TBL] [Abstract][Full Text] [Related]
20. Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization.
Rose WC; Marathe PH; Jang GR; Monticello TM; Balasubramanian BN; Long B; Fairchild CR; Wall ME; Wani MC
Cancer Chemother Pharmacol; 2006 Jul; 58(1):73-85. PubMed ID: 16228206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]